Clinical Trial Update: Bioequivalence Trial of Alprazolam 0.25 mg Tablets [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence trial of Alprazolam 0.25 mg tablets completed for Anxiety Disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders

Drugs mentioned

• Alprazolam 0.25 mg tablets (alprazolam)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anxiety Disorders | Phase 1 | Status: COMPLETED